Filing Flows › Caribou Biosciences (CRBU) › Q4 2025
Caribou Biosciences (CRBU) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Mar 5, 2026
Caribou Biosciences (CRBU) reported revenue of $3.9M for the fourth quarter 2025 (Q4 2025), +90% from a year earlier and +79% from the quarter before. Operating margin was -722.0%, net loss $26.5M (672.1% of revenue).
Caribou Biosciences, Q4 2025: revenue $3.9M (+90% year over year), operating margin -722.0%, net loss $26.5M, operating cash flow −$20.8M. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $3.9M | +79% | +90% |
| Operating profit | −$28.5M | — | — |
| Net earnings | −$26.5M | — | — |
| Operating cash flow | −$20.8M | — | — |
What changed
Revenue was $3.9M in Q4 2025, up 90% year over year and up 79% from the previous quarter.
Operating costs exceeded revenue by $28.5M, an operating margin of -722.0%. Total costs fell 21% while revenue rose 90%. The quarter ended with a net loss of $26.5M, narrower than the previous quarter's $27.5M loss.
Operating cash flow was −$20.8M. Non-cash charges added back $682K of depreciation and amortization and $2.7M of share-based compensation. Working capital and other items added $2.2M. Capital expenditures of −$216K exceeded it, leaving free cash flow of −$20.6M.
Questions
What was Caribou Biosciences' revenue in the fourth quarter 2025?
Caribou Biosciences (CRBU) reported revenue of $3.9M for the fourth quarter 2025 (Q4 2025), +90% from a year earlier and +79% from the quarter before.
Was Caribou Biosciences profitable in the fourth quarter 2025?
Operating loss was $28.5M (-722.0% of revenue) and net loss $26.5M.